[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356888-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356888-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","stage-specific-biomarkers-in-triple-negative-breast-cancer-preliminary-findings-from-bioinformatics-approaches","Stage-specific biomarkers in triple-negative breast cancer - Preliminary findings from bioinformatics approaches","","Integrated bioinformatics approaches were used to identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer (TNBC). Microarray data covering early-, advanced-, and normal samples, together with RNA-seq datasets, enabled differential gene expression discovery. Weighted Gene Co-expression Network Analysis (WGCNA), STRING protein–protein interaction mapping, and miRNA co-regulation evaluation supported biomarker selection. Validation used UALCAN and immunohistochemistry, while molecular docking guided drug repurposing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/stage-specific-biomarkers-in-triple-negative-breast-cancer-preliminary-findings-from-bioinformatics-approaches/356888/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/stage-specific-biomarkers-in-triple-negative-breast-cancer-preliminary-findings-from-bioinformatics-approaches/356888.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the study on TNBC biomarkers?","Question",{"text":63,"@type":64},"To identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer using integrated bioinformatics methods.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and analyses were used to discover biomarkers?",{"text":68,"@type":64},"Microarray and RNA-seq TNBC datasets were analyzed to find differentially expressed genes, followed by WGCNA for co-expression, STRING for protein–protein interactions, and multiMiR/TCGA-based correlation for miRNA co-regulation.",{"name":70,"@type":61,"acceptedAnswer":71},"How were candidate genes and drug targets validated?",{"text":72,"@type":64},"Candidate genes were validated with UALCAN and immunohistochemistry data, while molecular docking was used to assess potential therapeutic agents and highlight repurposable drugs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356888,1790173931,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Stage-speciﬁc biomarkers in triple-negative breast cancer:  \nPreliminary ﬁndings from bioinformatics approaches  \nFaeze Shahraki 1, Azadeh Meshkini 1  and Elham Nazari2  \nCancer Biomarkers Vol. 43(0): 1–21 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/18758592261454886](DOI: 10.1177/18758592261454886)[ ](DOI: 10.1177/18758592261454886)[journals.sagepub.com/home/cbm](journals.sagepub.com/home/cbm)  \nAbstract  \nBackground: Integrated bioinformatics approaches were used to identify stage-speciﬁc candidate genes and potential drug targets in triple-negative breast cancer (TNBC).  \nMethods: Microarray (164 early-stage, 33 advanced-stage, and 53 normal samples) and RNA-seq (113 normal, 163 earlystage, and 30 advanced-stage TNBC samples) datasets were analyzed. Differentially expressed genes (DEGs) were identiﬁed, followed by co-expression analysis using Weighted Gene Co-expression Network Analysis (WGCNA) and protein–protein interaction analysis using the STRING database. miRNA co-regulation was evaluated using multiMiR and TCGA correlation analyses. Candidate genes were validated using UALCAN and immunohistochemistry data. Molecular docking assessed potential therapeutic agents.  \nResults: Novel stage-speciﬁc candidate biomarkers were identiﬁed, including DNAJC6, SKP2, MOCOS, and NCAPD2 in early-stage TNBC, and F11R, FOXO6, PPP4C, and TMEM51 in advanced-stage TNBC. UALCAN analysis conﬁrmed the dysregulation of these genes across 23 additional malignancies. STRING-based network analysis revealed stage-speciﬁc protein–protein interactions, including SKP2–SKP1 in early-stage and F11R–TJP1 in advanced-stage TNBC. miRNA coregulation distinguished early-stage TNBC through PI3K–AKT–related pathways and advanced-stage TNBC through tumor progression–associated pathways. Docking-based drug repurposing highlighted conventional agents (e.g., doxorubicin) and potential novel candidates (e.g., sunitinib).  \nConclusion: This study identiﬁes novel stage-speciﬁc gene candidates and suggests repurposable drugs for TNBC, supporting progression-speciﬁc targeted therapeutic strategies.  \nKeywords  \nTriple-Negative breast cancer (TNBC), cancer staging, microarray gene expression proﬁles, drug repurposing, bioinformatics  \nReceived: 29 April 2025; accepted: 12 May 2026  \nIntroduction  \nTriple-negative breast cancer (TNBC) is an aggressive, heterogeneous breast cancer subtype. Its lack of targeted therapies poses signiﬁcant diagnostic and therapeutic challenges.1 Unlike other subtypes, TNBC lacks the three key receptors—Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor-2 (HER2)—that are commonly targeted in breast cancer treatments.2 Consequently, unlike other breast cancer subtypes, TNBC is insensitive to hormonal  \n1 Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran  \n2Department of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \nCorresponding author:  \nAzadeh Meshkini, Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran.  \nEmail: [a.meshkini@um.ac.ir](a.meshkini@um.ac.ir)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution  \nNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us](https://us). [sagepub.com/en-us/nam/open-access-at-sage](sagepub.com/en-us/nam/open-access-at-sage)).  \nand HER2-targeted therapies. This leaves patients with limited treatment o","cbCaivRG45l5t3la","https://ap.wps.com/l/cbCaivRG45l5t3la","pdf",6554118,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the purpose of the study on TNBC biomarkers?\",\"answer\":\"To identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer using integrated bioinformatics methods.\"},{\"question\":\"Which datasets and analyses were used to discover biomarkers?\",\"answer\":\"Microarray and RNA-seq TNBC datasets were analyzed to find differentially expressed genes, followed by WGCNA for co-expression, STRING for protein–protein interactions, and multiMiR/TCGA-based correlation for miRNA co-regulation.\"},{\"question\":\"How were candidate genes and drug targets validated?\",\"answer\":\"Candidate genes were validated with UALCAN and immunohistochemistry data, while molecular docking was used to assess potential therapeutic agents and highlight repurposable drugs.\"}]","Stage-specific biomarkers in triple-negative breast cancer - Preliminary findings from bioinformatics approaches | PDF",1790128092,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23b93825c20d798a1584514cac63eea3.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94ab556a6f33165d9a0e80e2602a3867.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b24afed1a1b2c9808ff4f4fbf81dba90.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f20aa3ffea924a357115a37a17b95e9.webp",980,1306]